PLX vs T · P/E 31, rev $53.4M vs P/E 7.4, rev $125.65B
Protalix Biotherapeutics Inc (PLX) versus AT&T Inc. (T) — a side-by-side from cached financials, not a winner call.
Protalix Biotherapeutics Inc (PLX) is a biotechnology company listed on US.
AT&T Inc. (T) is a telecom services company listed on NYSE. It is led by John Stankey.
Latest reported PLX revenue for 2024-12-31 was $53.4M. Net income was $2.9M. Revenue was down 18.5% from 2023-12-31 to 2024-12-31. PLX currently screens at market cap $122.6M and trailing P/E 30.8.
Latest reported T revenue for 2025-12-31 was $125.65B. Net income was $21.95B. Revenue was up 2.7% from 2024-12-31 to 2025-12-31. T currently screens at market cap $155.92B and trailing P/E 7.4.
PLX currently screens at market cap $122.6M and trailing P/E 30.8. T currently screens at market cap $155.92B and trailing P/E 7.4.
Not investment advice. Open the PLX and T stock pages for the full models.
Not investment advice.